Chimerix updates stakeholders on clinical trials for AdVise, SUPPRESS and smallpox vaccine

In North Carolina, Chimerix recently updated stakeholders on clinical trials for several products – including AdVise, SUPPRESS and smallpox vaccinations.
The mission of Chimerix is to find, create and release new oral medications to combat conditions where there is a high unmet medical need. Throughout the years, the company has developed an oral antiviral called Brincidofovir, which is a clinical stage medication.
Dr. Michael Grimley, associate professor in the division of bone marrow transplant and immune deficiency at Cincinnati Children’s Hospital, said that open label pilot of AdVise showed patients who have adenovirus infection could possibly survive when the drug was administered.
The Phase 3 SUPPRESS trial is ongoing. In this trial, doctors are trying to determine whether SUPPRESS prevents cytomegalovirus (CMV) in bone marrow transplant patients. The third trial that company officials discussed was the use of Bincidofovir as a treatment for smallpox in case of a terror attack or accidental release. Smallpox is a contagious disease that has no specific treatment, although researchers are developing vaccines, according to the Centers for Disease Control and Prevention.